Chemours price target lowered to $30 from $32 at Barclays

Barclays lowered the firm’s price target on Chemours to $30 from $32 and keeps an Equal Weight rating on the shares after its Q4 results. The Audit Committee resolution and the company’s introduction of its new CEO Dignam were positive steps, but more fundamental questions emerge from earnings on TiO2 market share and Fluoro growth, the analyst tells investors in a research note. There is high investor expectation for the 2024 earnings growth of the Thermal & Specialized Solutions segment, so while the company is not providing guidance at this time, there is new investor caution here, the firm added.